目的 研究CRLF2过表达的急性B淋巴细胞白血病（B‑cell acute lymphoblastic leukemia, B‑ALL）患儿的临床特征及其预后影响。 方法 回顾性选取2018年10月—2022年10月于四川省妇幼保健院和昆明市儿童医院收治的B‑ALL患儿为研究对象。根据初诊时CRLF2基因检测情况，分为CRLF2过表达组与对照组，比较两组患儿临床特征及预后情况。 结果 共纳入93例B‑ALL患儿，其中CRLF2过表达组29例，对照组64例，发病年龄为2~12岁。CRLF2过表达组在初诊时肝脾大、血小板减少的比例显著低于对照组（P<0.05），初诊时出现包块的比例显著高于对照组（P<0.05）。CRLF2过表达组的CRLF2蛋白表达量较对照组显著升高（P<0.05）。CRLF2过表达组患儿3年平均无事件生存率和总生存率分别为75.9%、85.9%，均低于对照组（90.1%、91.0%），但差异无统计学意义（P>0.05）。 结论 CRLF2过表达可能对B-ALL的疾病进展有一定作用，其预后价值需扩大样本量进一步验证。

Objective To study the clinical features and prognostic impact of CRLF2 overexpression in children with B-cell acute lymphoblastic leukemia (B-ALL). Methods A retrospective study included pediatric B-ALL patients admitted to Sichuan Provincial Maternity and Child Health Care Hospital and Kunming Children's Hospital from October 2018 to October 2022. Patients were divided into a CRLF2 overexpression group and a control group without CRLF2 overexpression according to CRLF2 gene testing at initial diagnosis. Clinical features and prognosis between groups were compared. Results A total of 93 children with B-ALL were enrolled, including 29 with CRLF2 overexpression. The age of onset ranged from 2 to 12 years. At diagnosis, the proportions of hepatosplenomegaly and thrombocytopenia in the CRLF2 overexpression group were significantly lower than those in the control group (P<0.05), while the proportion of masses was significantly higher (P<0.05). Significantly higher CRLF2 protein expression in the CRLF2 overexpression group than in the control group (P<0.05). The mean 3-year event-free survival (EFS) and overall survival (OS) rates in the CRLF2 overexpression group were 75.9% and 85.9%, respectively, lower than the control group (90.1% and 91.0%, respectively), but the differences lacked statistical significance by log-rank test. Conclusions These findings suggest a potential role of CRLF2 overexpression in disease progression. Further studies with larger sample sizes are warranted to confirm its prognostic significance.